Marine Drugs (Nov 2021)

A Novel Angiotensin-I-Converting Enzyme (ACE) Inhibitory Peptide from <i>Takifugu flavidus</i>

  • Yongchang Su,
  • Shicheng Chen,
  • Shuilin Cai,
  • Shuji Liu,
  • Nan Pan,
  • Jie Su,
  • Kun Qiao,
  • Min Xu,
  • Bei Chen,
  • Suping Yang,
  • Zhiyu Liu

DOI
https://doi.org/10.3390/md19120651
Journal volume & issue
Vol. 19, no. 12
p. 651

Abstract

Read online

Alcalase, neutral protease, and pepsin were used to hydrolyze the skin of Takifugu flavidus. The T. flavidus hydrolysates (TFHs) with the maximum degree of hydrolysis (DH) and angiotensin-I-converting enzyme (ACE)-inhibitory activity were selected and then ultra-filtered to obtain fractions with components of different molecular weights (MWs) (50 kDa). The components with MWs 50) of 0.58 mg/mL. Purification and identification using semi-preparative liquid chromatography, Sephadex G-15 gel chromatography, RP-HPLC, and LC–MS/MS yielded one new potential ACE-inhibitory peptide, PPLLFAAL (non-competitive suppression mode; IC50 of 28 μmmol·L−1). Molecular docking and molecular dynamics simulations indicated that the peptides should bind well to ACE and interact with amino acid residues and the zinc ion at the ACE active site. Furthermore, a short-term assay of antihypertensive activity in spontaneously hypertensive rats (SHRs) revealed that PPLLFAAL could significantly decrease the systolic blood pressure (SBP) and diastolic blood pressure (DBP) of SHRs after intravenous administration. These results suggested that PPLLFAAL may have potential applications in functional foods or pharmaceuticals as an antihypertensive agent.

Keywords